NOVTNovanta Inc.

$141.41+23% 1Y
Latest close: back above its 200-day averageOct 9, 2026what changed →

Is the business good?

Mixed

The checks split: earnings fully cash-backed (1.9×), but margins compressing.

1 good, 1 to watch, 2 neutral
Fundamental health (F-score)5 / 9SEC EDGAR · Dec 31, 2025

Mixed fundamental signals. Nine pass/fail tests of year-over-year health from the filings.

Profits arrive as cash1.87×derived · Jul 3, 2026

Operating profit is fully backed by cash. Conversion is improving vs a year ago.

Margin direction, 3 years−3.8 pts

Operating profit is falling even as sales grow, costs are outrunning the top line.

Where ROE comes from3% ROA

A balanced mix of margins, efficiency, and leverage. ROE 5% = margin × turnover × leverage.

Unless marked, from derived.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

FCF conversionbetter than 84% of the market
Leverage (Debt/EBITDA)better than 72% of the market

Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.

How good a business is NOVT?

Novanta Inc. earns 6.5% on the capital it employs against a 9.0% cost of capital, so growth costs more than it returns.

6.5%

Return on invested capital · cost of capital 9.0% · 2.5 points below what the capital costs: growth destroys value

Operating margin
9.0%

Operating margin · Scientific & Technical Instruments median 16% · 12 months to Q2 2026

Cash conversion
1.87×

Cash conversion · 1.55× a year ago · operating cash flow covers the operating profit after tax

Share count, year on year
+14%

Share count, year on year · shareholders own a smaller slice than a year ago

Operating margin by fiscal year
YearOperating margin
FY20209.5%
FY20219.1%
FY202212%
FY202313%
FY202412%
FY20259.6%
Details›
Gross margin12 months to Q2 2026
45%
Operating margin12 months to Q2 2026
9.0%
Net margin12 months to Q2 2026
6.0%
Free cash flow margin
11%
R&D as % of revenue
9.2%
Revenue, trailing twelve months
$1.03B
Free cash flow, trailing twelve months
$114M
Net income, trailing twelve months
$62M
Return on invested capitaloperating profit after tax ÷ debt + equity − cash
6.5%

Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.